XOMA Royalty Corp.

NASDAQ:XOMA

Biotechnology

Healthcare
$40.17 +0.44%

+$0.19 today

Market cap
$503.77M
Beta
0.87
P/E (TTM)
15.8
EPS (TTM)
$2.65
52W Low $22.29High $42.81

Volume 4.22M

Average 0.21M

XOMA Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

XOMA Royalty Corp.NASDAQ: XOMA

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables turns positive

Q1 FY2026 accounts receivables was $325K, compared with -$3.71M a year earlier. Trailing-twelve-month accounts receivables was $1.6M.

Context

  • Accounts receivables amounted to 4.7% of revenue in FY2025, up 1.7 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near $325K or moves back toward the trailing-twelve-month quarterly average of $401K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$325K+126.2% QoQ
Last fiscal yearDec 2025
-$2.43M+190.5% YoY
LTMMar 2026
$1.6M+128.9% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+108.8%——
1 year+190.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(2.43M) USD
Year-over-year change
-190.5%

Accounts Receivables vs competitors

How XOMA compares with its peers on the latest reported figures

  • XOMA's LTM Mar 2026 accounts receivables of $1.6M is the 2nd largest of the 10 companies compared; the peer median is $0.
  • Its year-over-year change of +128.9% is the 2nd highest of 5, against a peer median of -51.3%.
  • Accounts receivables amounts to 4.4% of revenue for XOMA, versus a peer median of 25.7%.
XOMA Competitors Peer median
Accounts Receivables for XOMA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AUTLAutolus Therapeutics plcLTM Mar 2026$13.46M -6.1%—14.5%
XOMAXOMA Royalty Corp.LTM Mar 2026$1.6M +128.9%—4.4%
QSIQuantum-Si incorporatedLTM Mar 2026$683K +174.7%—36.9%
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$49.73K -134.1%——
BNTCBenitec Biopharma Inc.LTM Mar 2026$8.07K -96.4%+481.9%—
DSGNDesign Therapeutics, Inc.LTM Mar 2026$0 ———
SLDBSolid Biosciences Inc.LTM Mar 2026$0 ———
AURAAura Biosciences, Inc.LTM Mar 2026$0 ———
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$0 ———
GALTGalectin Therapeutics Inc.LTM Mar 2026$0 ———
Peer median (excluding XOMA) $0-51.3%+481.9%25.7%

Competitors are the stored peer set for XOMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income15.8M(17.1M)(40.83M)(13.82M)31.71M
Depreciation & Amortization7K104K900K216K2.97M
Deferred Income Tax000(5.66M)103K
Stock-Based Compensation6.2M3.61M9.1M10.31M9.27M
Change in Working Capital(886K)(181K)(3.53M)(2.79M)(11.37M)
Accounts Receivables1.58M208K(1M)(835K)(2.43M)
Inventory00000
Accounts Payables765K1.85M(523K)1.6M(10.6M)
Other Working Capital(3.23M)(2.23M)(2M)(3.55M)1.65M
Other Non-Cash Items1.56M694K16.2M(2.01M)(29.82M)
Operating Cash Flow22.68M(12.88M)(18.16M)(13.75M)2.87M
Capital Expenditures(26.5M)(15.25M)(17K)(20K)0
Acquisitions (Net)000(1.25M)3.85M
Purchases of Investments000(3.24M)(99K)
Sales of Investments00000
Other Investing Activities(26.5M)(4.97M)(694K)(23.75M)47.14M
Investing Cash Flow(26.5M)(20.22M)(711K)(28.26M)50.89M
Debt Repayment(4.25M)0130M(6.9M)(10.6M)
Common Stock Issued1.58M2.42M466K5.21M8.72M
Common Stock Repurchased00(148K)(13K)(16.04M)
Dividends Paid(3.5M)(5.47M)(5.47M)(5.47M)(5.47M)
Other Financing Activities(21M)(1.4M)(3.79M)1.26M(3.07M)
Financing Cash Flow12.84M(4.45M)120.59M(11.13M)(26.46M)
Effect of Forex Changes00000
Net Change in Cash9.01M(37.55M)101.72M(53.13M)27.29M
Free Cash Flow(3.82M)(28.13M)(18.18M)(13.77M)2.87M

XOMA Royalty Corp.

NASDAQ:XOMA

Intrinsic Alpha fair value

Locked

Current Price

$40.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.